Table 2.
Abstinence and Retention Outcomes
| Buprenorphine Taper Group | Clinic Attendance Requirement | |||||||
|---|---|---|---|---|---|---|---|---|
| Outcome Measure | 28-day (n=28) | 56-day (n=25) | Daily (n=20) | 2-3 days/wk (n=33) | ||||
| Primary Outcome | Mean [95% CI]a | Mean [95% CI] | p-value | Effect Size [95%CI]b | Mean [95% CI]c | Mean [95% CI] | p-value | Effect Size [95%CI]b |
| % opioid negative (all scheduled urinalyses - ITT) | 17.2 [5.8, 28.6] | 34.6 [23.2, 50.0] | .039 | 0.57 [0.02, 1.13] | 8.6 [0.0, 21.6] | 43.2 [33.0, 53.4] | <.001 | 1.20 [0.58, 1.81] |
| % opioid negative (while retained in treatment) | 23.2 [11.4, 34.9] | 41.7 [29.9, 53.5] | .035 | 0.59 [0.03, 1.14] | 13.6 [0.0, 27.1] | 51.4 [40.8, 62.0] | <.001 | 1.25 [0.63, 1.87] |
| % opioid negative (only samples obtained) | 31.0 [17.3, 44.7] | 55.9 [42.2, 69.6] | .017 | 0.68 [0.11, 1.25] | 20.6 [4.7, 36.6] | 66.2 [53.7, 78.7] | <.001 | 1.28 [0.66, 1.90] |
| Secondary Outcomes | ||||||||
| Days retained in treatment | 26.4 [19.6, 32.9] | 37.5 [30.8, 44.3] | .027 | 0.63 [0.06, 1.19] | 17.3 [9.5, 25.0] | 46.7 [40.6, 52.8] | <.001 | 1.70 [1.04, 2.35] |
| Longest Duration of Opioid Abstinence (days) | 7.3 [1.3, 13.6] | 16.3 [10.0, 22.6] | .053 | 0.55 [−0.02, 1.11] | 4.7 [0.0, 11.9] | 19.0 [13.4, 24.6] | .003 | 0.88 [0.30, 1.49] |
a
Least square means from two-way ANOVA adjusted for attendance schedule
b
Effect sizes are expressed as Cohen's d.
c
Least square means from two-way ANOVA adjusted for taper group